Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent released polypeptide (GIP) binding site , is showing promising data in preliminary clinical trials . Current research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/